Magnus Helgesson, Linnea Kjeldgård, Emma Björkenstam, Syed Rahman, Klas Gustafsson, Heidi Taipale, Antti Tanskanen, Lisa Ekselius, Ellenor Mittendorfer-Rutz
Sustainable labour market participation among working young adults with diagnosed attention deficit/hyperactivity disorder (ADHD)
SSM - population health
due low number individuals hiv2 randomised trials hiv2 treatment ever done hypothesised noncomparative study describing outcomes several antiretroviral therapy art regimens parallel groups would improve understanding differences hiv1 hiv2 might lead different therapeutic approaches pilot phase 2 noncomparative openlabel randomised controlled trial done burkina faso cte divoire senegal togo adults hiv2 art naive cd4 counts 200 cells per l greater randomly assigned 111 one three treatment groups computergenerated sequentially numbered block randomisation list stratified country used online allocation next available treatment group groups tenofovir disoproxil fumarate henceforth tenofovir dosed 245 mg daily either emtricitabine 200 mg daily lamivudine 300 mg daily triple nucleoside reverse transcriptase inhibitor nrti group received zidovudine 250 mg twice daily ritonavirboosted lopinavir group received lopinavir 400 mg twice daily boosted ritonavir 100 mg twice daily raltegravir group received raltegravir 400 mg twice daily primary outcome rate treatment success week 96 defined absence serious morbidity event followup plasma hiv2 rna less 50 copies per ml week 96 substantial increase cd4 cells baseline week 96 trial registered clinicaltrialsgov nct02150993 closed new participants jan 26 2016 june 29 2017 210 participants randomly assigned treatment groups five participants died 96 weeks followup triple nrti group n2 ritonavirboosted lopinavir group n2 raltegravir group n1 eight serious morbidity event triple nrti group n4 ritonavirboosted lopinavir group n3 raltegravir group n1 17 plasma hiv2 rna 50 copies per ml greater least triple nrti group n11 ritonavirboosted lopinavir group n4 raltegravir group n2 32 triple nrti group switched another art regimen 18 permanently discontinued art triple nrti group n5 ritonavirboosted lopinavir group n7 raltegravir group n6 data safety monitoring board recommended premature termination triple nrti regimen safety reasons overall treatment success rate 57 95 ci 4766 ritonavirboosted lopinavir group 59 4968 raltegravir group raltegravir ritonavirboosted lopinavir regimens efficient safe adults hiv2 regimens could compared future phase 3 trials results pilot study suggest trend towards better virological immunological efficacy raltegravirbased regimen anrs mie